Short Bowel Syndrome
- Home
- Solutions
- By Diseases
- Intestinal Diseases
- Short Bowel Syndrome
Short bowel syndrome develops when a individual has lost enough bowel length or function that the individual becomes malabsorptive and often needs lifelong parenteral support. Protheragen has specialized research services developed to enhance the understanding and therapy of short bowel syndrome by supporting the project needs of the researchers and scientists working in these areas.
The loss of a substantial portion of the intestine results in short bowel syndrome, which is classified as a rare disease occurring in adults and is the leading reason for chronic intestinal failure in adults. Malabsorption of nutrients, electrolytes, and fluids develops, is the main manifestation.
The variety in severity of short bowel syndrome varies quite significantly; ranging from singular micronutrient malabsorption to complete intestinal failure, the spectrum of short bowel syndrome depends on three factors: the remaining length of the small intestine, the anatomical portion of the remaining bowel, and the functionality of the remnant bowel. It is believed that the incidence of short bowel syndrome from benign causes is close to 2/million/year.
Fig.1 Results of small intestine bacterial overgrowth. (Caporilli, C., et al., 2023)
As a consequence of surgery resection for the small intestine induced the loss of bowel mass mostly, short bowel syndrome is a rare malabsorptive disorder. This condition in pediatric age is associated with congenital diseases along with perinatal conditions which include necrotizing enterocolitis (NEC), malrotation with midgut volvulus, gastroschisis along with intestinal atresia, whereas, the long segment type may include Hirschsprung's disease alongside extensive aganglionosis which is an uncommon cause but still exists.
Fig.2 The management of short bowel syndrome. (Radetic, M., et al., 2023)| Drug Names | Mechanism of Action | Targets | Research Phase |
| Teduglutide | Binds and activates GLP-2 receptors which mediate the release of IGF-1, nitric oxide, and KGF. | GLP-2R | Phase III |
| Glepaglutide | Possesses intestinotrophic and anti-inflammatory activity. | GLP-2R | Phase III |
| Apraglutide | Enhances the absorption of fluids and energy from the intestine. | GLP-2R | Phase II |
| Obeticholic acid (OCA) | Moderately improves intestinal barrier dysfunction and inhibits proinflammatory factors overexpression. | FXR | Preclinical |
| Hepatocyte growth factor (HGF) | Promotes intestinal adaptation and enterocyte proliferation. | / | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Being one of the most recognized specialized preclinical research services providers in short bowel syndrome research, we offer a wide array of customized services that aid in therapeutic development. Our devotion lies in the progression of gastrointestinal disease development, which starts from identifying disease targets and modeling, to drug development and preclinical research.
Animal models present great value in understanding some related aspects such as pathophysiology and therapy procedures. We specialize in animal model development for short bowel syndrome and offer tailored services to clients conducting research in the field of gastrointestinal diseases.
Small bowel surgical resection in animal models is done to produce a state that mimics short bowel syndrome resulting in malabsorption and other associated complications.
Protheragen focuses on breakthrough drug development for short bowel syndrome and offers services for pharmacokinetic studies as well as biosafety assessments. Teaming up with us to access cutting-edge expertise and resources for the research of short bowel syndrome, advancing research and therapeutic approaches for short bowel syndrome, a complex gastrointestinal disorder. If you are interested in our comprehensive services, please do not hesitate to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.